Company  

Renovion is a ventured backed, clinical stage company with a Board of Directors that has deep expertise in early-stage pharmaceuticals, clinical operations, funding strategies and corporate governance. ARINA-1 has the potential to change the lives of those many patients with limited therapeutic options. The Board is committed to maximizing this opportunity to benefit patients’ lives.

Dan-Copeland.jpg
Dan Copeland
Chief Executive Officer

Dan was the founder and president of Emerge Life Sciences, a consulting company focused on new and emerging technologies in the life science space with significant work in translational medicine and devices over the last decade. Prior to this, he focused on commercialization of respiratory products for asthma and COPD with GSK.

zamora headshot.png
Marty Zamora, MD
Chief Medical Officer

Dr. Zamora received his M.D. from the University of Colorado and then  specialized in Pulmonary and Critical Care Medicine. He joined the faculty at the University of Colorado and started the Lung Transplant Program where he served as the Medical Director for 27 years.  He is now Professor Emeritus of Medicine, Division of Pulmonary Sciences and Critical Care Medicine at the University of Colorado School of Medicine.  As Principal and Founder of MRZ Biomedical Consulting, he actively works with pharmaceutical and device companies involved with ex-vivo organ preservation and lung transplant. Dr. Zamora has extensive experience with early and late stage pulmonary drug development and FDA interactions. 

Dr. Zamora continues to remain active in basic, clinical, and translational research with previous NIH and foundation support. He has published several book chapters and over 150 articles / abstracts in peer-reviewed journals. He has been awarded honors such as America's Top Doctors and Best Doctors in America, The Faculty Gold Headed Cane Award. He serves on committees and boards in numerous professional societies, such as the American Society of Transplantation and UNOS, as well as the Alpha-1 Foundation.

Marilyn Thompson
Finance

Marilyn has over 25 years of experience as a business development executive in the biotech, pharma, medical device, software and 3D scanning sectors. She has served as a Controller, Director of Finance and Chief Financial Officer with oversight of Accounting, Finance and Administrative areas of business. She has extensive experience in new business and federal grant reporting and auditing. She has also served as a consultant to over 100 start-up companies.

DSCF2221_edited.jpg
Carolyn Durham, PhD
Chief Scientific Officer

 Carolyn received a PhD in Mucosal Immunology from UAB and was a Howard Hughes Fellow in Translational Medicine. After a post-doc at UNC, she was the Scientific Advisor of Montague Capital, focusing on scientific strategy and collaboration. She has spearheaded the transition of ARINA-1 from 15 years of research to product commercialization.

Marilyn Thompson_accounting_2020_10-13.j
Hal Craig_2020-09-28.jpg
Hal Craig
Chemistry, Manufacturing, and Controls
Strategy and Operations

Hal is the founder of Trout Creek Consulting, LLC, a strategy and life science supply chain consultancy focused on solving CMC, strategic and technical challenges. As an experienced operating executive with over 30 years in FDA-regulated industries, he has held multiple roles with responsibilities including global business units, supply chain, quality and regulatory, engineering and maintenance, capital projects, and commercial real estate. His expertise includes manufacturing, product / process development and strategic planning.

Sarah Callahan headshot.jpg
Sarah Callahan
Director of Clinical Operations

Sarah has been in the clinical research industry since 2005. She started her career at Inspire Pharmaceuticals, where she spent 7 years, focused primarily on monitoring and managing clinical trials for a cystic fibrosis drug candidate. She then worked on the CRO side for over 10 years, providing program and department level oversight across multiple project teams in various indications.